Terms ending in 2042
Every in-force patent on Precision Biosciences, Inc.'s record whose computed term ends in 2042, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 12,410,418 | Optimized Engineered Meganucleases Having Specificity for a Recognition Sequence in the Hepatitis B Virus Genome In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 11,866,747 | Engineered Meganucleases That Target Human Mitochondrial Genomes In force · Medium confidence | Precision Biosciences, Inc. | In force | Medium confidence | |
| US 12,752,019 | Engineered Meganucleases Having Specificity for a Recognition Sequence in the Hydroxyacid Oxidase 1 Gene In force · High confidence | Precision Biosciences, Inc. | In force | High confidence | |
| US 12,697,400 | Gene Editing Methods for Treating ALPHA-1 Antitrypsin (AAT) Deficiency In force · High confidence | Precision Biosciences, Inc. | In force | High confidence |
4 of 4 patents shown. Soonest term end first, then patent number.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.